Clinical Trials Logo

Androgen Deprivation Therapy clinical trials

View clinical trials related to Androgen Deprivation Therapy.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04062162 Active, not recruiting - Prostate Cancer Clinical Trials

Walking Football as a Supportive Medicine for Patients With Prostate Cancer

Start date: July 11, 2019
Phase: N/A
Study type: Interventional

Androgen deprivation therapy (ADT) is widely used in men with prostate cancer (PCa) to delay disease progression and enhance survival. The use of ADT is often associated with a vast spectrum of side effects that considerably reduce quality of life. Exercise has been proposed as a non-pharmacological strategy to counter some adverse effects of ADT among patients with PCa. Particularly, recreational football-based interventions have been suggested as an enjoyment approach to involve patients with PCa in regular exercise practice. Given its intermittent nature and vigorous efforts, adverse events associated with recreational football practice have been reported. To handle this issue and to involve patients with PCa in recreational football practice, walking football has emerged as a more suitable exercise modality

NCT ID: NCT03867357 Active, not recruiting - Clinical trials for Metastatic Prostate Cancer

Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia

Start date: December 7, 2018
Phase:
Study type: Observational

Prostate cancer (PCa) is the most common cancer among men and is even more common in the military and veteran population. For patients with advanced prostate cancer, the most common treatment includes lowering the levels of the hormone testosterone as much as possible. This is called "androgen deprivation therapy" or "ADT". Unfortunately, ADT also causes patients to be fatigued, weak and to loose muscle. This is often referred to as "sarcopenia" and it leads to falls, poor quality of life and higher risk of death. Currently, there is no treatment for sarcopenia because the investigators do not understand the mechanisms that cause it. The mitochondria is the part of the cells responsible for providing energy to muscles but to this date the investigators do not know if it is affected in prostate cancer patients with sarcopenia due to ADT. The overall goal of this proposal is to establish if the mitochondria is responsible for sarcopenia in patients with prostate cancer receiving ADT. The investigators will measure mitochondrial function, muscle mass and strength, and feelings of fatigue and quality of life in patients with prostate cancer before starting and after 6 months of ADT.